Hypera (OTCMKTS:HYPMY) Hits New 12-Month High at $9.33
Hypera (OTCMKTS:HYPMY) Hits New 12-Month High at $9.33
Hypera S.A. (OTCMKTS:HYPMY – Get Rating)'s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $9.33 and last traded at $9.22, with a volume of 112502 shares trading hands. The stock had previously closed at $9.08.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group upgraded shares of Hypera from a "neutral" rating to a "buy" rating in a research report on Monday.
Get Hypera alerts:Hypera Trading Up 1.5 %
The firm has a 50-day moving average of $8.42 and a two-hundred day moving average of $7.96.
About Hypera
(Get Rating)Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Read More
- Get a free copy of the StockNews.com research report on Hypera (HYPMY)
- Is Netflix A Blockbuster Or Another Blockbuster Video?
- Intel – Are We Near A Bottom?
- Merck Nears Breakout Point After October Surprise Good News
- Target Is About To Start A 20% Rally Into The Holidays
- Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
Hypera S.A. (OTCMKTS:HYPMY – Get Rating)'s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $9.33 and last traded at $9.22, with a volume of 112502 shares trading hands. The stock had previously closed at $9.08.
Hypera S.A.(OTCMKTS: HYPMY — 获取评级)的股价在周三的交易中创下52周新高。该股交易价格高达9.33美元,最后一次交易价格为9.22美元,交易量为112502股。该股此前收于9.08美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测增长
Separately, The Goldman Sachs Group upgraded shares of Hypera from a "neutral" rating to a "buy" rating in a research report on Monday.
另外,高盛集团在周一的研究报告中将Hypera的股票评级从 “中性” 上调至 “买入”。
Hypera Trading Up 1.5 %
Hypera 交易量上涨1.5%
The firm has a 50-day moving average of $8.42 and a two-hundred day moving average of $7.96.
该公司的50天移动平均线为8.42美元,两百天移动平均线为7.96美元。
About Hypera
关于 Hypera
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Hypera SA作为一家制药公司在巴西运营。它提供 Adacne、Addera、apri、AmpliumG 下的处方产品,请 Celestamine、Celestone、Celestone Soluspan、Cizax、diciprax、Dirmotil Fusid、Digedrat、diprosalic、diprosone、diprosone、diprosalic、diprosone、diprosone、Diprosan、Emprol XR、Flow、Garasone、Halobex、Librox panon、moon、Lydian、macrodantin、maxSulid、milgamma、Mioflex — A、nesina、Novotram、oximax、predal、pressaliv、Quadridem、Rizi M、softalm、tacroz、tinodin、umma 和 velunid 品牌。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Hypera (HYPMY)
- Is Netflix A Blockbuster Or Another Blockbuster Video?
- Intel – Are We Near A Bottom?
- Merck Nears Breakout Point After October Surprise Good News
- Target Is About To Start A 20% Rally Into The Holidays
- Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
- 免费获取 StockNews.com 关于 Hypera (HYPMY) 的研究报告的副本
- Netflix 是大片还是另一部大片视频?
- 英特尔——我们接近谷底了吗?
- 十月出人意料的好消息之后,默克接近突破点
- 塔吉特即将在假期开始上涨20%
- 强生有足够的Alpha来成为稳健的低贝塔股票吗?
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Hypera Daily 的新闻和收视率 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Hypera及相关公司最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧